Haute Autorité de Santé

ZALTRAP aflibercept, anti-VEGF, Cancérologie – nouveau médicament FOLFIRI, n’apporte pas d’amélioration du service médical rendu ASMR V, inexistante, dans la prise en charge du cancer colorectal métastatique résistant ou ayant progressé après un traitement à base d’oxaliplatine, Documents , ZALTRAP 24072013 AVIS CT12847 ZALTRAP_24072013_SYNTHESE_CT12847 …

Aflibercept Plus FOLFIRI for Second-line Treatment of

Background: The objectives of this study were to evaluate the safety profile of aflibercept and health-related quality of life HRQL in patients with metastatic colorectal cancer mCRC provided with aflibercept access before marketing authorization, Patients and methods: Patients received aflibercept followed by FOLFIRI fluorouracil, leucovorin, irinotecan on day 1 of a 2-week cycle until

Aflibercept Plus FOLFIRI as Second-Line Treatment for

Forty-nine patients receiving aflibercept–FOLFIRI as second-line treatment were identified, 40,8% of whom were aged over 65 years, The majority of patients had multi-organ metastases 73,5%, and had previously received bevacizumab in combination with chemotherapy CT as first-line treatment 79,6%, Median overall survival OS and progression-free survival PFS were 13 and 6 months

Phase II trial of aflibercept with FOLFIRI as a second

Aflibercept 4 mg/kg plus FOLFIRI was administered every 2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity or patient withdrawal, Tumors were imaged every 6 weeks, The primary endpoint was objective response rate ORR; secondary endpoints were progression-free survival, overall survival, safety, and pharmacokinetics of aflibercept, irinotecan and 5

Folfiri-Aflibercept vs, Folfiri-Bevacizumab as Second Line

Background: There are no clinical studies comparing the efficacy of bevacizumab vs,aflibercept in association with folfiri in RAS mutated RAS-M metastatic colorectal cancer patients mCRC pretreated with folfox and bevacizumab,Patients and Methods: Consecutive RAS-M unresectable mCRC patients progressing to first-line folfox/bevacizumab were treated with 12 cycles of folfiri/bevacizumab

Disease Control With FOLFIRI Plus Ziv-aflibercept

Background: The prognosis of patients with metastatic colorectal cancer mCRC is poor, especially after failure of initial systemic therapy, The VELOUR study showed modestly prolonged overall survival OS with ziv-aflibercept plus 5-fluorouracil, leucovorin, and irinotecan zFOLFIRI vs, placebo+FOLFIRI after progression on 5-fluoruracil, leucovorin, and oxaliplatin FOLFOX ± bevacizumab,

Folfiri-Aflibercept vs, Folfiri-Bevacizumab as Second Line

Thus, folfiri/aflibercept is a further suitable option in second-line treatment of RAS-M mCRC patients, To date there are no randomized studies to drive the selection of the best anti-angiogenic drug bevacizumab beyond progression vs, aflibercept after failure of the first-line chemotherapy in RAS-M mCRC patients, The present study is the first one reporting results on …

ZALTRAP aflibercept : nouvelle spécialité dans la prise

Date de publication : févr, 05, 2014Temps de Lecture Estimé: 4 mins

ZALTRAP 25 mg/ml solution à diluer pour perfusion IV aflibercept constitue un nouveau traitement anti-VEGF du cancer colorectal métastatique pour les pati

Chimiothérapie du cancer du côlon, indications, effets

Fichier PDF

un passage au Folfiri-aflibercept ^peut être proposé , la dernière option étant l’introduction des anti-EGFR, Si le traitement a comporté d’emblée une bi-chimiothérapie et un anti-EGFR en cas de tumeur Ras non mutée, il faut changer la chimiothérapie et introduire en seconde ligne le bevacizumab, L’algorithme d’utilisation de ces différentes protocoles reste complexe et de

Aflibercept : substance active à effet thérapeutique

L’aflibercept agit comme un récepteur leurre soluble qui se lie au VEGF-A, avec une plus haute affinité que ses récepteurs natifs, ainsi qu’aux ligands apparentés PlGF et VEGF-B, En agissant comme piège à ligand, l’aflibercept empêche la liaison des ligands endogènes à leurs récepteurs apparentés et, de ce fait, bloque la signalisation médiée par le récepteur, L’aflibercept

Aflibercept

Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor PlGF agent, has recently been approved by the U,S, Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan FOLFIRI for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen,

Aflibercept Zaltrap

Aflibercept pronounced ay-flib-er-set is a targeted cancer drug and is also known by its brand name, Zaltrap, It is a treatment for advanced bowel cancer, You usually have it together with the chemotherapy combination FOLFIRI, And only if you have already had the chemotherapy drug oxaliplatin, How it works, Aflibercept works by stopping cancer cells from making new blood vessels, This is

Zaltrap

Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid, The medicine contains the active substance aflibercept, How is Zaltrap used? Zaltrap can only be obtained with a prescription and treatment should be supervised by a doctor who is experienced in using cancer medicines, Zaltrap is given as an infusion drip into the vein

Irinotecan with 5FU and folinic acid

FOLFIRI is named after the initials of the drugs used in the treatment, The drugs are: FOL – folinic acid; F – fluorouracil 5FU IRI – irinotecan, Fluorouracil is often called 5FU, which is the name we use in this information, You might hear folinic acid being called calcium folinate or leucovorin, Folinic acid is not a chemotherapy drug, It is often given alongside 5FU because it has